HHS Gave a $1.6 Million Grant to a Controversial Vaccine Study. These Emails Show How That Happened

The HHS quietly posted a $1.6 million no-bid grant on Dec. 18 to fund a randomized trial in Guinea-Bissau proposed by Danish researchers Peter Aaby and Christine Stabell Benn that would withhold the hepatitis B birth dose from half of ~14,000 newborns; emails show the request was funneled through advisers to HHS Secretary Robert F. Kennedy Jr. and tied to matching support (Pershing Square pledged $1.8M conditional on matching funds). The award coincided with a policy shift at CDC to stop universal hepatitis B birth-dose recommendations and has drawn broad ethical condemnation, requests to halt or redesign the trial, and reputational and governance risk for HHS and CDC leadership—risks that could affect future funding priorities and international public-health partnerships.

Analysis

Market structure: The HHS decision and back-channel funding distort incentives toward ideologically aligned research; winners in the near term are small niche anti-establishment research groups and reputationally-aligned funders while large diversified pharma (JNJ, PFE) and global public-health contractors could face reputational and demand volatility. If the U.S. policy shift spreads to other high-income markets, pediatric vaccine unit volumes for hepatitis B and related combos could decline 1–3% of vaccine revenue industry-wide over 12–36 months, pressuring specialty vaccine developers disproportionately.

Risk assessment: Tail risks include a WHO/UN funding pullback or large litigation class action (low probability, high impact) that could force major grant reversals and pause trials — material for small-cap vaccine makers but immaterial to diversified big pharmas. Immediate (days) risk is media-driven volatility; short-term (weeks–months) risk centers on ACIP/HHS reversals and Africa CDC/Guinea-Bissau trial suspensions; long-term (quarters–years) risk is policy diffusion and donor reallocation away from Gavi-like programs.

Trade implications: Favor defensive big-pharma and diagnostics exposure (JNJ, PFE, ABT, BDX) and underweight small-cap, single-product vaccine names (NVAX, vaccine-focused microcaps) and biotech ETFs (XBI) until ACIP/HHS clarity. Options: buy 3-month 10% OTM puts on NVAX sized to 1% portfolio risk and sell 3-month covered calls on PFE at 5% OTM to harvest premium; establish pair trade long PFE (2% portfolio) / short NVAX (1–1.5% portfolio) to capture relative safety.

Contrarian angles: The market may overstate structural demand loss — hepatitis B is a low-single-digit share of top pharma revenues, so sell-offs in large diversified names are likely overdone while short interest should be concentrated in vaccine-specialists. Watch for a policy reversion signal (ACIP vote reversal or WHO endorsement) as a binary catalyst that could restore 5–15% of collapsed small-cap vaccine valuations; limit short positions to <2% portfolio with 20% stop-loss to avoid rapid reversals.

Key Decisions for Investors

• Establish a 1.5–2.0% portfolio long position in JNJ and PFE (split equally) within 7 trading days to hedge reputational/volatility risk — target hold 6–12 months; trim if ACIP/HHS issues full re-recommendation or if either stock outperforms by +10% from entry.
• Initiate a 1.0% portfolio short position in NVAX (or nearest pure-play vaccine microcap) within 5–30 days, with a hard stop-loss at 20% adverse move and profit-taking at 30% gain, targeting headline-driven downside and trial/approval risk.
• Buy 3-month NVAX 10% OTM puts equal to 1% portfolio risk as a volatility play; simultaneously sell 3-month PFE 5% OTM covered calls on 0.5–1.0% of holdings to monetize elevated short-term premium.
• Rotate 2–3% portfolio from EM-focused public-health ETFs/SMIDs into diagnostics/medical device leaders (ABT, BDX) over 30–90 days to capture potential screening demand if birth-dose policy increases prenatal screening; re-evaluate on ACIP decision within 60 days.